Results 1 to 10 of about 3,657 (192)
The role of delamanid in the treatment of drug-resistant tuberculosis [PDF]
Therapeutics and Clinical Risk Management, 2015 Joseph M Lewis,1 Derek J Sloan2,3 1Tropical and Infectious Disease Unit, Royal Liverpool University Hospital, Liverpool, UK; 2Liverpool School of Tropical Medicine, Pembroke Place, Liverpool, UK; 3Liverpool Heart and Chest Hospital, Liverpool, UK ...
Joseph Lewis, Derek James Sloan
exaly +11 more sources
Delamanid: Safety and Efficacy Analysis
Туберкулез и болезни лёгких, 2023 The review presents the analysis of 50 publications describing treatment of multiple drug resistant tuberculosis with regimens containing the new drug of delamanid.
G. N. Mozhokina +3 more
doaj +3 more sources
Delamanid Resistance: Update and Clinical Management
Clinical Infectious Diseases, 2020 Abstract Delamanid, a-first-in-class bicyclic nitroimidazole, was recently approved for multidrug-resistant tuberculosis treatment. Pitted against the hope for improving treatment outcomes is the threat of the rapid resistance emergence.
Richard Anthony, Anne-Laure Bañuls
exaly +7 more sources
Profile of delamanid for the treatment of multidrug-resistant tuberculosis
Drug Design, Development and Therapy, 2015 John D Szumowski,1,2 John B Lynch11Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, WA, USA; 2Division of AIDS Medicine, Santa Clara Valley Medical Center, San Jose, CA, USA Abstract: New approaches
Szumowski JD, Lynch JB
doaj +6 more sources
Delamanid or pretomanid? A Solomonic judgement! [PDF]
Journal of Antimicrobial Chemotherapy, 2022 Abstract Given the low treatment success rates of drug-resistant tuberculosis (TB), novel TB drugs are urgently needed. The landscape of TB treatment has changed considerably over the last decade with the approval of three new compounds: bedaquiline, delamanid and pretomanid. Of these, delamanid and pretomanid belong to the same class of
Saskia E. Mudde +4 more
openaire +5 more sources
Delamanid is a new anti-tuberculosis drug: use, limitations, and prospects [PDF]
Туберкулез и болезни лёгких, 2021 The review analyses 61 publications on the use of delamanid, a new drug for the treatment of drug resistant tuberculosis. It presents information about pharmacokinetic parameters, efficacy and safety, as well as the place of delamanid in the combination ...
V. N. Zimina, I. B. Viktorova
doaj +3 more sources
PLOS Global Public Health, 2023 Clarity about the role of delamanid in longer regimens for multidrug-resistant TB is needed after discordant Phase IIb and Phase III randomized controlled trial results.
Carly A Rodriguez +30 more
doaj +2 more sources
Journal of Microbiology, Immunology and Infection, 2023 Background/Purpose(s): Bedaquiline and delamanid were recently approved for multidrug resistant tuberculosis (MDR-TB). Bedaquiline carries a black box warning of increased risk of death compared to the placebo arm, and there is a need to establish the ...
Ju Hwan Kim +7 more
doaj +2 more sources
International Journal of Mycobacteriology, 2023 Background: Drug-resistant tuberculosis (DR-TB) is a public health concern that is difficult to treat, requiring long and complex treatment with highly effective drugs.
Oki Nugraha Putra +3 more
doaj +2 more sources
Prevalence of Mycobacterium tuberculosis resistant to bedaquiline and delamanid in China
Journal of Global Antimicrobial Resistance, 2021 : Objectives: The new antituberculous drugs delamanid and bedaquiline form the last line of defence against drug-resistant tuberculosis (TB). Understanding the background prevalence of resistance to new drugs can help predict the lifetime of these drugs’
Wencong He +11 more
doaj +1 more source